Arrhythmias in Fabry cardiomyopathy

Clinical Cardiology

Volumn 35, Issue 12, 2012, Pages 738-740

  Acharya, Deepak ^a   Robertson, Peter ^a   Neal Kay, G ^a   Jackson, Leslie ^b   Warnock, David G ^b   Plumb, Vance J ^a   Tallaj, José A ^a,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOMYOPATHY; CLINICAL ARTICLE; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; FABRY CARDIOMYOPATHY; FABRY DISEASE; FAINTNESS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HOLTER MONITOR; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MALE; MEDICAL RECORD REVIEW; TREATMENT INDICATION;

EID: 84870946067     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22047     Document Type: Article

References (27)

1. Garman SC, Garboczi DN., The molecular defect leading to Fabry disease: structure of human α-galactosidase. J Mol Biol. 2004; 337: 319 -335.
2. Weidemann F, Niemann M, Warnock DG, et al. The Fabry cardiomyopathy: models for the cardiologist. Annu Rev Med. 2011; 62: 59 -67.
3. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249 -254.
4. Houge G, Skarbovik AJ., Fabry disease-a diagnostic and therapeutic challenge [in Norwegian]. Tidsskr Nor Laegeforen. 2005; 125: 1004 -1006.
5. Mehta A, Widmer U., Natural history of Fabry's disease. In:, Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from 5 Years of FOS. Oxford, UK: Oxford Pharmagenesis; 2006.
6. Linhart A., The heart in Fabry's disease. In:, Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives from 5 Years of FOS. Oxford, UK: Oxford Pharmagenesis; 2006.
7. Magage S, Linhart A, Bultas J, et al. Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male. Echocardiography. 2005; 22: 333 -339.
8. Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis. 2001; 24 (suppl 2): 75 -83.
9. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with Fabry disease: natural history data from the Fabry Registry. J Am Coll Cardiol. 2011; 57: 1093 -1099.
10. Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011; 4: 592 -601.
11. Frustaci A, Chimenti C., Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation. 2007; 116: e350 -e351.
12. Igawa O, Miake J, Hisatome I., Ventricular tachycardias and dilated cardiomyopathy caused by Fabry disease. Pacing Clin Electrophysiol. 2005; 28: 1142 -1143.
13. Pinderski LJ, Strotman J., Congestive heart failure in Fabry cardiomyopathy: natural history experience in an international cohort of 1,448 patients. J Heart Lung Transplant. 2006; 25: S70.
14. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005; 96: 842 -846.
15. Ikari Y, Kuwako K, Yamaguchi T., Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J. 1992; 68: 323 -325.
16. O'Mahony C, Coats C, Cardona M., Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Eurospace. 2011; 13: 1781 -1788.
17. Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008; 51: 50 -59.
18. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450 -458.
19. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743 -2749.
20. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001; 345: 9 -16.
21. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001; 345: 25 -32.
22. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003; 108: 1299 -1301.
23. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 2004; 66: 158 -165.
24. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008; 94: 153 -158.
25. Pierre-Louis B, Kumar A, Frishman WH., Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev. 2009; 17: 31 -35.
26. Linhart A, Kampmann K, Zamorano JL, et al. Cardiac manifestations of Anderson Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007; 28: 1228 -1235.
27. US Food, and Drug Administration. http://www.fda.gov/downloads/Drugs/ DrugSafety/DrugShortages/UCM187056.pdf. Accessed December 8, 2011.